LSD-Based DT120 Delivers Promising Depression Relief in Phase III Trial

Definium Therapeutics reports that a single 100‑microgram dose of its LSD‑based DT120 significantly reduced major depressive disorder symptoms versus placebo in a 149‑participant Phase III trial across 20 sites, with a week‑6 average 8.1‑point greater drop on a standard depression scale, about 35% of DT120 users achieving a 50%+ improvement (vs 7% placebo), and 12% in remission (vs 3%), with effects persisting through 12 weeks. The company plans FDA expedited review pending results from a second Phase III trial (Ascend) and continued development of DT120 for anxiety disorders, signaling potential for rapid, durable relief from a single treatment if approved.